Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 35

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 35
---
DTs, and FDA-approved diagnostic tests and therapeutic
products considered experimental or investigational or which are used for disease indications without FDA marketing authorization. Even
if we succeed in bringing any tests or products to the market, they may not be considered cost effective, and governmental or third-party
reimbursement might not be available or sufficient. If adequate governmental or third-party coverage is not available, we may not be able
to maintain price levels sufficient to realize an appropriate return on our investment in research and development for new tests and products.
In addition, legislation and regulations affecting the pricing of diagnostic tests, pharmaceuticals, or healthcare services may change
in ways adverse to us before or after any of our proposed tests and products are approved for marketing.

| 17 |

Our internal information technology systems, or those of our third-party clinical research organizations or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our diagnostic tests’ or therapeutic product candidates’ development programs, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.

We are increasingly dependent upon information technology
systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit confidential
information (including but not limited to intellectual property, proprietary business information, and personal information). It is critical
that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have also outsourced
elements of our operations to third parties, and as a result we manage a number of third-party contractors who have access to our confidential
information.

Despite the implementation of security measures, given
their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology
systems and those of our third-party clinical research organizations and other contractors and consultants are potentially vulnerable
to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, and telecommunication
and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants,
business partners, and/or other third parties, or from cyberattacks by malicious third parties (including the deployment of harmful malware,
ransomware, extortion, account takeover attacks, degradation of service attacks, denial-of-service attacks, “phishing,” or
social engineering and other means to affect service reliability and threaten the confidentiality,